Trials / Completed
CompletedNCT00473590
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | 15 mg/kg administered by intravenous infusion |
| DRUG | Bortezomib | 1.3 mg/m\^2 administered by intravenous bolus injection |
| DRUG | placebo | Intravenous repeating dose |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2007-05-15
- Last updated
- 2017-06-14
- Results posted
- 2012-01-19
Source: ClinicalTrials.gov record NCT00473590. Inclusion in this directory is not an endorsement.